Stuart A. Arbuckle - Feb 17, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 17, 2023
Transactions value $
-$2,022,835
Form type
4
Date filed
2/22/2023, 03:30 PM
Previous filing
Feb 16, 2023
Next filing
Feb 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$1.32M -4.5K -5.95% $292.85 71.1K Feb 17, 2023 Direct
transaction VRTX Common Stock Sale -$6.11K -21 -0.03% $291.01 71.1K Feb 21, 2023 Direct F1
transaction VRTX Common Stock Sale -$160K -545 -0.77% $292.77 70.5K Feb 21, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$323K -1.1K -1.56% $293.74 69.4K Feb 21, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$217K -736 -1.06% $294.58 68.7K Feb 21, 2023 Direct F1, F2, F5
holding VRTX Common Stock 140 Feb 17, 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07).
F4 Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19).
F5 Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96).